CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer

Mayu Shiomi1 | Shinya Matsuzaki1,2,3 | Satoshi Serada4 | Koji Matsuo3,5 | Chihiro Mizuta-Odani1 | Mariko Jitsumori1 | Ruriko Nakae6 | Satoko Matsuzaki3,7 | Satoshi Nakagawa1 | Kosuke Hiramatsu1 | Ai Miyoshi3 | Eiji Kobayashi1 | Toshihiro Kimura1 | Yutaka Ueda1 | Kiyoshi Yoshino1,8 | Tetsuji Naka4 | Tadashi Kimura1

1Department of Obstetrics and Gynecology, Osaka University, Osaka, Japan
2Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan
3Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
4Center for Intractable Immune Disease, Kochi Medical School, Kochi University, Kochi, Japan
5Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
6Department of Obstetrics and Gynecology, Sumitomo Hospital, Osaka, Japan
7Department of Obstetrics and Gynecology, Osaka General Medical Center, Osaka, Japan
8Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Kitakyushu, Japan

Correspondence
Shinya Matsuzaki, Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
Email: zacky@gyne.med.osaka-u.ac.jp
Satoshi Serada, Center for Intractable Immune Disease, Kochi Medical School, Kochi University, Kohasu, Okocho, Nankoku, Kochi 783-8505, Japan.
Email: serada@kochi-u.ac.jp

Abstract
This study aimed to investigate the cytotoxicity of a cluster of differentiation 70 antibody-drug conjugate (CD70-ADC) against ovarian cancer in in vitro and in vivo xenograft models. CD70 expression was assessed in clinical samples by immunohistochemical analysis. Western blotting and fluorescence-activated cell sorting analyses were used to determine CD70 expression in the ovarian cancer cell lines A2780 and SKOV3, and in the cisplatin-resistant ovarian cancer cell lines A2780cisR and SKOV3cisR. CD70 expression after cisplatin exposure was determined in A2780 cells transfected with mock- or nuclear factor (NF)-κB-p65-small interfering RNA. We developed an ADC with an anti-CD70 monoclonal antibody linked to monomethyl auristatin F and investigated its cytotoxic effect. We examined 63 ovarian cancer clinical samples; 43 (68.3%) of them expressed CD70. Among patients with advanced stage disease (n = 50), those who received neoadjuvant chemotherapy were more likely to exhibit high CD70 expression compared to those who did not (55.6% [15/27] vs 17.4% [4/23], P < .01). CD70 expression was confirmed in A2780cisR, SKOV3, and SKOV3cisR cells. Notably, CD70 expression was induced after cisplatin treatment in A2780 mock cells but not in A2780-NF-κB-p65-silenced cells. CD70-ADC was cytotoxic to A2780cisR, SKOV3, and SKOV3cisR cells, with IC50 values ranging from 0.104 to 0.341 nmol/L. In A2780cisR and SKOV3cisR xenograft models, tumor growth in CD70-ADC treated mice was significantly inhibited compared to that in the control-ADC treated mice (A2780cisR: 32.0 vs 1639.0 mm3, P < .01; SKOV3cisR: 232.2 vs 584.9 mm3, P < .01). Platinum treatment induced CD70 expression in ovarian cancer cells. CD70-ADC may have potential therapeutic implications in the treatment of CD70 expressing ovarian cancer.

Abbreviations: ADC, antibody-drug conjugate; CD70, cluster of differentiation 70; FACs, fluorescence-activated cell sorting; MMAF, monomethyl auristatin F; mRNA, messenger ribonucleic acid; NACT, neoadjuvant chemotherapy; NHL, non-Hodgkin lymphoma; OvCA, ovarian cancer; PBS, phosphate-buffered saline; PDS, primary debulking surgery; PHH3, phosphor-histone H3; RCC, renal clear cell carcinoma; RCT, randomized-controlled trial; siRNA, small interfering RNA; WB, western blot.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
1 | INTRODUCTION

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States, with 13,940 registered ovarian cancer deaths in 2020.\(^1\) Platinum agents are key chemotherapeutic drugs currently used as a first-line OvCA treatment\(^2,3\); however, women with recurrent OvCa treated with second-line or later-line therapeutic agents have a median survival of 9-12 months with a response rate of approximately 20% for subsequent therapies.\(^4-6\)

Several chemotherapeutic and target therapy agents have been evaluated in clinical trials for recurrent OvCa, including cytotoxic agents, target therapy, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors; however, these agents exhibit only modest clinical responses.\(^6-11\)

Antibody-drug conjugates are novel therapeutic agents that enhance the therapeutic indices of cytotoxic anticancer agents by combining the antigen selectivity of a monoclonal antibody with the cytotoxicity of an anticancer drug.\(^12\) The pace of clinical trials for ADC is accelerating, with the number of agents evaluated in clinical trials being increased by more than three times in the last 5 years.\(^13\) To date, more than 150 ADCs have been investigated in clinical trials and more than 35 ongoing clinical trials for treatment-refractory solid tumors have been published to date;\(^12-14\) however, the currently available ADCs demonstrate modest survival effects in patients with OvCa.\(^15\)

Cluster of differentiation 70 is a member of the tumor necrosis factor superfamily and the ligand for CD27.\(^16,17\) It was first identified in activated T- and B-lymphocytes. The binding of CD70 to CD27 on activated lymphocytes signals the co-stimulation of T, B, and natural killer cells,\(^18,19\) and also regulates cell differentiation and T-helper 1/2 switching.\(^20\) CD70 is frequently expressed in various malignant diseases, including renal clear cell carcinoma (RCC 60%) and non-Hodgkin lymphoma (NHL 87%),\(^21,22\) but is minimally expressed in normal tissues.\(^23\)

Previous studies have shown that anti-CD70 monoclonal antibodies (CD70 mAb) and CD70-ADC (CD70 mAb conjugate with MMAF) exhibit antitumor effects in xenograft models of CD70 malignant diseases, such as lymphoma, NHL, and RCC.\(^21,24-26\) Based on the positive results of preclinical studies, a phase-I study of CD70-ADC in patients with CD70-positive relapsed/refractory NHL or metastatic RCC was conducted; however, CD70-ADC exhibited modest effects on these diseases with tolerable side effects.\(^22\)

Studies that examined OvCa cells/clinical samples\(^27-29\) have reported that CD70 is expressed in OvCa cells and is a potential predictor of platinum resistance.\(^30\) Given that the effectiveness of CD70-ADC therapy in patients with OvCa has been poorly studied, we examined the antitumor activity of CD70-ADC in OvCa cases.

2 | MATERIALS AND METHODS

Detailed information is provided in Document S1.

2.1 | Patient and tissue samples

Sixty-three high-grade serous OvCa surgical specimens were obtained from women who had undergone surgical treatment between 2012 and 2020 at Osaka University Hospital (Table S1). The histopathological analysis and diagnosis of the tissues were performed by board-certified gynecologic pathologists. Informed consent was obtained from the patients prior to sample collection and examination. Tumor staging was based on the 2014 International Federation of Gynecology and Obstetrics staging system.\(^31\) The study was approved by the Institutional Review Board of Osaka University Hospital (Approval No. 18236).

Among 63 OvCa surgical specimens, there were 29 women who received NACT before cytoreductive surgery. Of those, nine women underwent surgical biopsy before NACT in our institution and three women were excluded from the investigation as the samples were too small to perform immunohistochemistry. Thus, the expression of CD70 was compared before and after NACT in six patients (Table S2).

2.2 | Immunohistochemistry

All clinical samples were paraffin-embedded, fixed in 10% neutral buffered formalin, sliced into 4-µm tissue sections, deparaffinized, and rehydrated in graded alcohols. Immunostaining was performed using mouse monoclonal anti-CD70 antibody (MAB2738; R&D Systems) as the primary antibody, followed by the Vectastain ABC kit (Vector Laboratories) as previously described.\(^23,32-35\) The immunostained sections were photographed using a Visualix Pro2 camera (Olympus).

Three cases with advanced renal cell cancer (clear cell carcinoma) were immune-stained as positive controls.\(^36\) and three healthy ovari specimens were used as negative controls\(^38\) (formalin-fixed, paraffin-embedded sections were obtained from surgical treatment cases at Osaka University Hospital).

The intensity and density of positive staining were scored by three independent gynecological pathologists (SM, RN, and MS).
who were blinded to clinico-pathological information, as described in the Supporting Information Materials and Methods section.

2.3 | Cell lines and culture

The human ovarian carcinoma cell lines A2780 and SKOV3 were obtained from the European Collection of Authenticated Cell Culture (Salisbury, Scotland) and the American Type Culture Collection (Manassas, VA, USA), respectively.37 The human ovarian carcinoma cell lines OVISE, OVTOKO, and RMG-1 were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan). RMG-1 was cultured in Ham’s F12 medium (Thermo Fisher Scientific Inc.) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (Nacalai Tesque). A2780, SKOV3, OVTOKO, and OVISE were cultured in RPMI 1640 medium (FUJIFILM Wako Pure Chemical Corporation, Ltd) containing 10% FBS (Hyclone Laboratories), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO2. The identity of each cell line was confirmed by DNA fingerprinting using short tandem repeat profiling.32,33,38

2.4 | Establishment of cisplatin (platinum)-resistant cells

To develop platinum-resistant OvCA cell lines, A2780 and SKOV3 cells were treated with increasing concentrations of cisplatin;39 these cells were designated A2780cisR and SKOV3cisR. A2780 paclitaxel-resistant cell lines were generated using a similar method. Platinum-resistant cell lines were designated as A2780cisR and SKOV3cisR, and the paclitaxel-resistant cell line was designated as A2780pacR.

2.5 | Western blotting

The cells were prepared as described previously.23,32-34 The proteins were transferred to polyvinylidene difluoride membranes and incubated with goat polyclonal anti-CD70 antibody (1:500, sc-1741; Santa Cruz Biotechnology). Subsequently, the western blotting (WB) samples were incubated with donkey anti-goat horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10 000, sc-2020; Santa Cruz Biotechnology). In an investigation of CD70, NFkB- p65, and AP-1 expression after cisplatin exposure, rabbit monoclonal anti-CD70 antibody (1:500, sc-1741; Santa Cruz Biotechnology). Subsequently, the western blotting (WB) samples were incubated with donkey anti-goat horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10 000, sc-2020; Santa Cruz Biotechnology).

2.6 | Fluorescence-activated cell sorting analysis

The cells were washed in phosphate-buffered saline (PBS) (Nacalai Tesque) and detached with 0.02% ethylenediaminetetraacetic acid solution (Nacalai Tesque).32,33,35 The cells were washed twice with fluorescence-activated cell sorting (FACS) buffer (PBS with 1% FBS and 0.1% sodium azide) and then incubated with mouse monoclonal antihuman CD70 antibody (1:50, clone Ki-24; BD Biosciences) as the primary antibody.

2.7 | Preparation and transfection of siRNA

To silence CD70 expression, siRNA-CD70 (Hs_TNFSF7_1; #3; Qiagen) against CD70 was transfected using Lipofectamine RNAiMAX reagent (#13778150; Invitrogen) as previously described.32,38 Selective silencing of CD70 was confirmed by WB analysis. For cytotoxicity assays, the cells were seeded onto 96-well plates after a 4-h transfection, and measurements were performed on day 7.

For NFkB-p65 knockdown, siRNA-NFkB-p65 (#6261, Cell Signaling Technology) against NFkB-p65 was transfected as aforementioned. NFkB-p65-silencing cells were designated as A2780-NFkB-p65-silencing cells. Selective silencing of NFkB-p65 expression was confirmed by WB analysis.

2.8 | CD70 expression after cisplatin exposure

After transfection of siRNA-NkB-p65 and control siRNA for 48 h, the A2780 cells were incubated with nontreated cells and 20 µmol/L cisplatin for 1, 4, 8, and 12 h, followed by the preparation of protein extracts. The prepared protein extract was analyzed by WB analysis using CD70, c-Jun, NF-xB-p65, and phospho-NF-xB-p65 antibodies.

2.9 | CD70 confirmation after paclitaxel exposure

The expression of CD70 was determined in A2780 cells by WB using the protein extracts at 1, 4, 8, and 12 h after administration of 10 nmol/L paclitaxel and 10 nmol/L paclitaxel exposing cells followed by the preparation of protein extracts.

2.10 | Real-time quantitative reverse transcription PCR

A2780-NF-kB-p65-silenced cells were incubated with 5 µM cisplatin for 0, 1, or 2 h, followed by RNA extraction for real-time quantitative RT-PCR. CD70 expression in A2780 cells was determined using RT-PCR. Total RNA extraction and cDNA synthesis were performed according to the manufacturer’s protocol.23,34 PCR was performed using TB Green Premix Ex Taq II (#RR820A, Takara Bio, Shiga, Japan) and specific primers. PCR primers were also purchased
was examined using hydrophobic interaction chromatography. The resultant ADC containing solution was filtered. The drug distribution in tumors was examined using hydrophobic interaction chromatography. The mAbs were conjugated with MMAF using a maleimide-cysteine method, wherein the mAb inter-chain disulfide bonds were first reduced with tris(2-carboxyethyl) phosphine at 37°C and the maleimide moiety of the drug was subsequently linked to the reduced cysteines. The drug distribution was examined using hydrophilic interaction chromatography.

2.11 ADC development

Using previously described methods,23 commercially available anti-human-CD70 mAb (voretuzumab, TAB-H76; Creative Biolabs)23 and isotype control human-IgG1 mAb (clone QA16A12; BioLegend) were used to generate CD70-ADC and control-ADC, respectively. MMAF was used as a payload for ADCs, and the conjugation was performed by Moradec LLC. The mAbs were conjugated with MMAF using a maleimide-cysteine method, wherein the mAb inter-chain disulfide bonds were first reduced with tris(2-carboxyethyl) phosphine at 37°C and the maleimide moiety of the drug was subsequently linked to the reduced cysteines.

Conjugated ADCs were separated from the free drug on Sephadex G-50 columns. Next, the buffer was replaced with PBS, and the resultant ADC containing solution was filtered. The drug distribution was examined using hydrophilic interaction chromatography.

2.12 Cytotoxicity assay

Cytotoxicity assays of anti-CD70 mAb, human-IgG1-isotype control antibody, CD70-ADC, control-ADC, and MMAF were performed. The cells were evaluated using a flat-bottomed 96-well white polystyrene plate (Thermo Fisher Scientific Inc.) and 1000 cells were seeded per well in RPMI containing 10% FBS. After 24 h of incubation, anti-CD70 mAb, human- IgG1-isotype control antibody, CD70-ADC, control-ADC, and MMAF were added at different concentrations in hexaplicate wells in a humidified 5% CO2 atmosphere. After incubation for 6 days at 37°C, cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) and luminescence values were measured using a microplate reader (Lumat XS LB9508; Berthold Technologies).

The results are reported as the IC50, defined as the concentration of a compound needed to reduce the viability by 50% compared with the control cells (control = 100%).

2.13 In vivo efficacy

All animal experiments were conducted according to the institutional ethical guidelines for animal experimentation of Osaka University (registered protocol number 28-032-013).23 The in vivo treatment schedule is presented in Figure S1.

A2780cisR and SKOV3cisR xenografted mice were randomly divided into three groups (n = 6) when the mean tumor size reached approximately 90 mm3. CD70-ADC (3 mg/kg), control-ADC (3 mg/kg), or PBS was intravenously administered in 100 µL of PBS every 4 days for a total of four days (days 0, 4, 8, and 12). The xenografted tumors were removed and weighed on day 28.

2.14 Phospho-histone H3 staining

To investigate the pharmacologic effect of CD70-ADC at the cellular level, PHH3, which is a mitotic marker, was examined.3,11-14 A2780cisR xenograft mice were intravenously administered with PBS, control-ADC (3 mg/kg), or CD70-ADC (3 mg/kg), and the tumors were excised 24 h later. The tumor sections were sliced into 4-µm formalin-fixed paraffin-embedded tissue sections.

PHH3 (Ser10) staining was recorded as the ratio of PHH3 positive cells to all tumor cells in five fields (×400 magnification).

2.15 Statistical analysis

The results are expressed as means with standard deviations for the in vitro data and as means with standard errors of the mean for the in vivo experiments. Student’s t test, Mann-Whitney U test, Kruskal-Wallis H test, Pearson’s chi-square test, and Fisher’s exact test were used to assess the difference between groups, as appropriate. All statistical analyses were based on two-tailed hypothesis. JMP 13 (SAS Institute) was used for statistical analysis. P values <.05 were considered significant.

3 RESULTS

3.1 CD70 was highly expressed in patients with OvCA who received NACT

CD70 expression in OvCA clinical samples was evaluated by immunohistochemistry (Table 1). There were 63 OvCA samples and all samples were of high-grade serous type. Of those, 22 (34.9%) and 21 (33.3%) were in the CD70-high and CD70-low groups, respectively (Figure 1A,B). On univariate analysis, CD70 expression was not associated with age, stage, residual disease, or serum CA-125 levels (all P > .05). The median follow-up duration was 33.0 (interquartile range [IQR] 19.5-52) months (Table S1). Women in the CD70-high group were more likely to receive NACT compared to those in the CD70-low/negative group (72.7% [16/22] vs 29.3% [12/41], P < .01; Table 1).

Among patients with stage III-IV (advanced) diseases (n = 50), 34 (68.0%) patients showed CD70 expression. Of those, 19 (38.0%) and 15 (30.0%) showed high and low CD70 expression. Among the patients with advanced OvCA, those in the NACT group were more likely to show high CD70 expression compared to those in the non-NACT group (55.6% [15/27] vs 17.4% [4/23], odds ratio 3.2, 95% confidence interval 1.2-8.3, P < .01; Table S3).
TABLE 1 Correlation between CD70 expression levels and clinicopathological characteristics in serous ovarian carcinoma

| Characteristics | CD70 high | CD70 low/negative | P value |
|-----------------|-----------|-------------------|---------|
| No. (%)         | n = 22    | n = 41            |         |
| Median age (years) | 61.5 (52-70) | 61 (52-70.5) | .76     |
| FIGO stage      |           |                   |         |
| I               | 2 (9.1%)  | 7 (17.1%)         | .99     |
| II              | 1 (4.6%)  | 3 (7.3%)          |         |
| III             | 16 (72.7%)| 25 (61.0%)        |         |
| IV              | 3 (13.6%) | 6 (14.6%)         |         |
| Residual disease* |         |                   |         |
| Yes             | 9 (40.9%) | 15 (36.6%)        | .79     |
| No              | 13 (59.1%)| 26 (63.4%)        |         |
| Serum CA-125 level |       |                   |         |
| Normal          | 3 (13.6%) | 7 (17.1%)         | .99     |
| Abnormal        | 19 (86.4%)| 34 (82.9%)        |         |
| NACT             |           |                   |         |
| Yes             | 16 (72.7%)| 12 (29.3%)        | <.01    |
| No              | 6 (27.3%) | 29 (70.7%)        |         |
| NACT regimen    |           |                   |         |
| TC              | 9 (56.2%) | 5 (41.7%)         |         |
| TC+Bev          | 7 (43.8%) | 6 (50.0%)         |         |
| DC              | 0 (0%)    | 1 (8.3%)          |         |
| Median FU (months) | 45 (26.3-61.3) | 30 (17-46) | .03     |

Note: Median (IQR) or number (percentage per column) is shown. Chi-square test or Student’s t test was performed for univariate analysis. Mann-Whitney U test was used to compare two groups with nonparametric data. Significant P values are given in bold font.

Abbreviations: Bev, bevacizumab; CD70, cluster of differentiation 70; DC, docetaxel and carboplatin; FIGO, International Federation of Gynecology and Obstetrics; FU, follow-up; IQR, interquartile range; NACT, neoadjuvant chemotherapy; TC, paclitaxel and carboplatin. *Residual disease after cytoreductive surgery.

Nine out of 29 women underwent surgical biopsy in the NACT group and three women were excluded from the investigation as the samples were too small to perform immunohistochemistry. Of those (n = 6), the expression of CD70 was examined before and after NACT in the same patients. Significantly higher intensity score was observed in the after NACT group compared to that in the before NACT group (Figure 1C; median score 6 vs 2, P = .03). These findings suggested that platinum-based NACT had the potential to induce CD70 expression in OvCA cells.

3.2 | Platinum-resistant OvCA cells overexpressed CD70

CD70 expression in OvCA cells was examined using WB and FACS. The cisplatin toxicity IC50 values in the cisplatin-resistant models (A2780cisR and SKOV3cisR cells) were significantly higher than those in their parental counterparts (344.1 vs 0.62 µmol/L and 45.6 vs 3.7 µmol/L, respectively [all P < .01]) (Table S4). WB results showed strong CD70 expression in A2780cisR and SKOV3cisR cells, moderate expression in SKOV3 cells, and no expression in A2780 cells (Figure 1D). CD70 overexpression in A2780cisR, SKOV3, and SKOV3cisR cells was confirmed using FACS (Figure 1E).

3.3 | Silencing CD70 did not affect cisplatin sensitivity or cell proliferation

To explore the CD70 expression effect on platinum sensitivity and cell proliferation in OvCA cells, CD70 expression was silenced using siRNA (Figures 2A and S2). On cytotoxicity analysis, the IC50 values of cisplatin were similar in two A2780cisR-CD70-silenced (363.1 and 382.6 µmol/L) and A2780cisR mock cells (372.7 µmol/L, P = .28 and P = .13, respectively). Similarly, no significant change in IC50 was observed in two variants of SKOV3cisR-CD70-silenced (74.0 and 77.3 µmol/L) and SKOV3cisR mock cells (72.9 µmol/L, P = .51 and P = .83, respectively) (Figure 2B). The proliferation rates of CD70-silenced A2780cisR, SKOV3, and SKOV3cisR cells were similar (Figure 2C).

3.4 | Cisplatin exposure induces CD70 expression

To explore the mechanism of CD70 induction after cisplatin administration, the expression levels of c-Jun and NF-κB-p65 were determined. The WB results revealed positive NF-κB-p65 and negative c-Jun expressions in A2780 cells (Figure 3A).

To examine the role of NF-κB-p65 in CD70 induction, CD70 messenger ribonucleic acid (mRNA) was measured in A2780 mock and A2780-NF-κB-p65-silenced cells (Figure 3B). The A2780 mock cells expressed progressively higher CD70 mRNA expression at 1 h (1.63, P = .04) and 2 h (2.99, P < .01) of treatment compared to the corresponding untreated cells. Conversely, CD70 mRNA expression after cisplatin treatment did not increase in A2780-NF-κB-p65-silenced cells, relative to that in the untreated cells (P = .06; Figure 3B).

CD70 expression was compared between the A2780 mock and A2780-NF-κB-p65-silenced cells after cisplatin treatment (Figures 3C and S3). The knockdown of NF-κB-p65 and phosphorylated NF-κB-p65 expression was confirmed by WB analysis. The expression of NF-κB-p65 and phospho-NF-κB-p65 continuously increased after 1, 4, 8, and 12 h of cisplatin exposure in A2780 mock cells. CD70 expression gradually increased in A2780 mock cells starting at 1 h of cisplatin exposure, whereas no significant change in CD70 expression was observed in A2780-NF-κB-p65-silenced cells. Concerning the paclitaxel exposure, CD70 was not induced in A2780 parent cells after 1, 4, 8, and 12 h of paclitaxel exposure and CD70 was not expressed in A2780-paclitaxel resistant cells (Figure 3D).
3.5 | The anti-CD70 mAb did not inhibit cell proliferation

As shown in Figure 4A, neither the anti-CD70 mAb nor the anti-human-IgG₁-isotype control antibody inhibited the cell proliferation of A2780, A2780cisR, SKOV3, and SKOV3cisR cell lines.

3.6 | Bioengineering of CD70-ADC

Each of the anti-CD70 mAb and the isotype control antibody was directly conjugated to MMAF (Figure 4B), with drug-to-antibody ratios of 3.59 and 3.64, respectively.

3.7 | CD70-ADC showed cytotoxicity in CD70-expressing OvCA cells

MMAF demonstrated cytotoxicity in OvCA cell lines, including those that were cisplatin-resistant; IC₅₀ values ranged from 19.5 to 67.8 nmol/L (Table S4). As MMAF has poor cell membrane permeability, CD70 mAb conjugated MMAF was more likely to be sensitive compared to unconjugated MMAF in CD70-expressing cells. CD70-ADC showed a concentration-dependent inhibition of tumor growth among the CD70-expressing cell lines A2780cisR (IC₅₀: 0.104 nmol/L), SKOV3 (IC₅₀: 0.205 nmol/L), and SKOV3cisR cells (IC₅₀: 0.341 nmol/L), whereas no such inhibition was observed in the CD70-nonexpressing cell line A2780 and in the control-ADC treated cells (Figure 4C and Table S5).
3.8 | Cisplatin sensitivity of tumors in mouse xenograft models

To determine the platinum sensitivity of tumors derived from A2780, A2780cisR, SKOV3, and SKOV3cisR cells, xenograft models were established for each cell line (Figure 5A-D). In A2780 and SKOV3 xenograft mice, the tumor growth rate was significantly lower in the cisplatin-treated than in the PBS-treated group (A2780: 841.9 vs 1991.5 mm$^3$, $P < .05$; SKOV3: 254.4 vs 706.4 mm$^3$, $P < .01$) (Figure 5A,B). In the SKOV3 xenograft mice, the tumor weight was significantly lower in the cisplatin than in the PBS group (263.3 vs 503.3 mg, $P < .05$) (Figure 5E).

In A2780cisR and SKOV3cisR xenograft mice, the growth rate of tumors (A2780cisR: 1548.4 vs 1829.8 mm$^3$, $P = .10$; SKOV3cisR: 605.0 vs 733.4 mm$^3$, $P = .45$) and weight on day 28 post-administration (A2780cisR: 1260 vs 1340 mg, $P = .75$; SKOV3cisR: 531.7 vs 561.7 mg, $P = .52$) were similar in the cisplatin and PBS-treated groups (Figure 5C-E).

3.9 | CD70-ADC significantly inhibited tumor growth in A2780cisR and SKOV3cisR xenograft models

The effects of CD70-ADC were evaluated in the A2780cisR- and SKOV3cisR-based xenograft models. SKOV3-xenografted tumors were not assessed because of the absence of CD70 expression (Figure S1). In the A2780cisR xenograft model, the tumor size (32.0 vs 1639.0 mm$^3$, $P < .01$) and weight (140 vs 983.3 mg, $P < .01$) on day 28 after administration were significantly lower in the CD70-ADC than in the control-ADC group (Figure 6A,B), with no significant total body weight loss in any group (Figure 6C). Likewise, in SKOV3cisR xenograft models, the tumor size (232.2 vs 584.9 mm$^3$, $P < .01$) and weight (260 vs 476.7 mg, $P < .01$) were significantly lower in the CD70-ADC than in the control-ADC group (Figure 6D,E), with no significant difference in body weight across all groups (Figure 6F). Similar tumor sizes were observed between the control-ADC and PBS groups (A2780cisR, $P = .92$; SKOV3cisR, $P = .20$) (Figure 6B,E).
To assess the pharmacological effect of CD70-ADC, immunohistochemistry was performed to assess the expression of the mitotic marker PHH3 (Ser10). A significantly higher percentage of mitotic cells was observed in the CD70-ADC-treated than in the control-ADC group (6.40% [IQR 4.85%-7.0%] vs 3.48% [IQR 3.0%-4.0%], P < .01) (Figure 6G, H). Conjugation with anti-CD70 mAb led to the successful delivery of MMAF into OvCA cells, where it induced mitotic arrest via the inhibition of tubulin polymerization.

4 | DISCUSSION

4.1 | Principal findings

The key findings of this study were as follows: (i) CD70 expression was induced when the OvCA cells were treated with cisplatin (this appeared to be mediated by the NF-κB transcription pathway); (ii) a significantly higher CD70 expression was observed in the NACT group compared to that in the non-NACT group; and (iii) CD70-ADC
exhibited a significant inhibitory effect in CD70-expressing OvCA cells, both in vitro and in vivo.

4.2 | Results

Recently, NACT use for advanced OvCA has been significantly increased.\(^{42-45}\) Approximately 10%-30% of women with advanced OvCA received NACT in the early 2000s, and the rate of NACT use has nearly doubled in the following decade.\(^{42,44}\) RCTs that demonstrated that NACT was noninferior concerning the overall survival compared to PDS may have influenced the adoption of NACT.\(^{46,47}\) Although previous RCTs have demonstrated the noninferior overall survival of NACT, some studies have shown that the recurrence risk (platinum-resistant OvCA) is higher with NACT use than with PDS.\(^{48,49}\) NACT use has a potential to induce the expression of CD70, and CD70-ADC may show an antitumor effect even in platinum-resistant OvCA when the tumor showed CD70 expression. Therefore, CD70-ADC may be an attractive agent for women with OvCA treated with NACT.

ADCs constitute a novel technology for targeting rapidly proliferating cells by combining monoclonal antibodies that are highly specific for tumor antigens with effective cytotoxic agents.\(^{50}\) Progress has been made in the clinical application of ADCs in several cancer types, and there are seven FDA-approved ADCs;\(^ {51}\) however, none of them is indicated for OvCA cases. IMGN853 is an ADC designed to target the folate receptor alpha, which is moderately or strongly expressed in 66% of patients with OvCA.\(^ {52}\) This ADC consists of a humanized anti-folate receptor alpha mAb attached via a cleavable disulfide linker to the cytotoxic maytansinoid DM4, which inhibits tubulin polymerization. Based on its favorable tolerability and activity in a phase 1/2 study,\(^ {53}\) a randomized phase 3 trial (FORWARD I) was conducted to compare the safety and efficacy of IMGN853 and single-agent chemotherapy in women with medium or high folate receptor alpha expression. Although IMGN853 is the most advanced ADC for OvCA that is presented under clinical development for OvCA, IMGN853 showed a modest improvement in progression-free survival (hazard ratio 0.98, \(P = .897\)) and overall survival rates (hazard ratio 0.81, \(P = .248\)).\(^ {13}\)
Several CD70-ADCs, including SGN-75 (MMAF-conjugated), SGN-70A (pyrrolobenzodiazepine-conjugated), and MDX-1203 (duocarmycin-conjugated), have been evaluated clinically to date. For targeting platinum-resistant OvCA via ADC, acquired cross-resistance between platinum drugs and other chemotherapeutic agents should be noted. Several studies have demonstrated that there is no cross-resistance between platinum drugs and antimicrotubule agents. Consistent with the findings in previous
studies, MMAF was effective in A2780cisR and SKOV3cisR cells (Table S4). Based on this finding, a CD70-ADC conjugated with MMAF was generated in this study. CD70-ADC significantly inhibited the proliferation of CD70-expressing OvCA cells in vitro and in vivo and the tolerability of CD70-ADC has been widely investigated in previous studies. Clinical trials are warranted to examine the efficacy of CD70-ADC in recurrent OvCA.

4.3 | Clinical implication

To the best of our knowledge, the mechanism of CD70 induction after cisplatin exposure has not been examined. Some transcription factors related to proliferation and platinum resistance may facilitate cell survival during cisplatin exposure; however, they seem not to induce CD70.
The transcription factors c-Jun and NF-κB have been reported to induce CD70 expression.59 As c-Jun was not expressed after cisplatin exposure in A2780 cells, we focused on NF-κB. Notably, quantitative RT-PCR assays showed that CD70 mRNA was not elevated in A2780-NF-κB-p65-silenced cells, whereas CD70 mRNA was elevated in A2780 mock-transfected cells. These results suggested that NF-κB-p65 expression may play a role in inducing CD70. Moreover, CD70 expression following platinum drug administration is an NF-κB-mediated pathway that may not be specific to OvCA cells, therefore this finding is crucial as it could be applicable to other malignancies.

4.4 | Research implications

Although CD70 was not found to be associated with proliferation, previous studies involving murine fibrosarcoma, melanoma, and colon cancer models have shown that CD70-CD27 signaling increases the number of CD4+CD25+Treg cells and promotes tumor growth and metastasis in vivo.60 To investigate the effect of CD70 on OvCA tumor prognosis in vivo, further investigation is warranted.

Our study focused on the inhibitory effect of CD70-ADC in OvCA cells. Based on our immunohistochemistry data, we hypothesized that platinum administration may induce CD70 expression in women with OvCA and this finding was confirmed in vitro. These findings suggested that platinum-based NACT followed by CD70-ADC administration may be effective therapies. Therefore, CD70-ADC could ultimately be effective for approximately 70% of patients with advanced OvCA (CD70-high/low).

Targeting platinum drug-induced membrane proteins via ADC is a novel concept. The relative and absolute quantification and comparison of membrane proteins in OvCA cells using methods such as isobaric tags before and after platinum treatment35,61,62 would be important to establish and design new treatment modalities for this disease.

4.5 | Strengths and limitations

To our knowledge, this is the first study to demonstrate that CD70 is induced in OvCA cells treated with cisplatin. Moreover, CD70-ADC demonstrated a therapeutic effect against CD70-expressing OvCA cells.

However, several limitations should be noted. First, CD70 expression was not examined in platinum-resistant OvCA clinical samples because they could not be obtained, therefore we could not determine the efficacy of CD70-ADC in a patient-derived xenograft mouse model of platinum-resistant OvCA. Second, as a human antibody was used to generate CD70-ADC, the adverse effects of CD70-ADC in xenograft models could not be investigated. As similar CD70-ADCs have been reported to be tolerable in clinical trials, ours may also be safe. Third, a multivariate analysis could not be performed between the CD70-high and CD70-low/negative groups because of the small sample size, therefore further studies including a larger number of cases are needed to assess the role of CD70 in OvCA prognosis.

Fourth, although CD70 was not associated with platinum resistance in vitro examination, the association between platinum/chemo resistance and the CD70 expression could not be determined because of the limited samples and various NACT regimens. Further studies that would examine the effect of CD70 expression on chemo resistance in clinical OvCA samples are warranted.

5 | CONCLUSION

CD70-ADC inhibits the proliferation of CD70 expressing OvCA cells both in vitro and in vivo. As the tolerability of CD70-ADC has been demonstrated in phase-1/2 clinical trials for treatment refractory malignancies, data from our preclinical OvCA models merit further investigation for OvCA in a clinical trial setting.

6 | ETHICAL COMMITTEE APPROVAL

Osaka University Institutional Review Board (No. 18236).

DISCLOSURE

Honorarium, Chugai, textbook editorial expense, Springer, investigator meeting attendance expense, VBL Therapeutics (KM), research grant, MSD (Sh.M.). Other authors report no conflicts of interest concerning the materials or methods used in this review or the findings specified in this paper. The authors have no competing financial interests related to this study.

ORCID

Shinya Matsuzaki https://orcid.org/0000-0001-5725-9994
Koji Matsuo https://orcid.org/0000-0002-6232-8701

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
2. Baldwin LA, Huang B, Miller RW, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612-618.
3. Matsuzaki S, Serada S, Morimoto A, et al. Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers. Expert Opin Ther Targets. 2014;18:403-414.
4. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
5. Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol. 2014;133:624-631.
6. Bogani G, Lopez S, Mantiero M, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020;158:484-488.
7. Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015-4022.
8. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian
cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.
9. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280-304.
10. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
11. Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Invest Drugs. 2010;19:1339-1354.
12. Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538-549.
13. Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019;153:694-702.
14. U. S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ (accessed 9/10/2020).
15. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev. 2016;68:3-19.
16. Goodwin RG, Alderson MR, Smith CA, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell. 1993;73:447-456.
17. Hintzen RQ, Lens SM, Koopman G, Pols ST, Spits H, van Lier RA. CD70 represents the human ligand for CD27. Int Immunol. 1994;6:477-480.
18. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 2008;12:341-351.
19. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol. 2005;17:275-281.
20. Wajant H. Therapeutic targeting of CD27 and CD70. Expert Opin Ther Targets. 2016;20:959-973.
21. McEarchern JA, Smith LM, McDonagh CF, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
22. Tannir NM, Forero- Torres A, Ramchandren R, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2010;103:617-621.
23. Nakae R, Matsuzaki S, Serada S, et al. CD70 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2018;142:1056-1066.
24. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther. 2005;4:2037-2044.
25. Law CL, Gordon KA, Toki BE, et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res. 2008;14:7763-7772.
26. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets. 2008;12:341-351.
27. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas. Mol Cancer Ther. 2005;4:2037-2044.
28. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation anticancer agent CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006;66:2328-2337.
29. McEarchern JA, Ofazoglou E, Francisco L, et al. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood. 2007;109:1185-1192.
30. Bayat P, Taghdisi SM, Rafatpanah H, Abnous K, Ramezani M. In vitro selection of CD70 binding aptamer and its application in a biosensor design for sensitive detection of SKOV-3 ovarian cells. Talanta. 2019;194:399-405.
31. Ryan MC, Kostner H, Gordon KA, et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer. 2010;103:676-684.
32. Michie CO, Sakala M, Rivans I, Strachan MW, Clive S. The frequency and severity of capcitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Br J Cancer. 2010;103:617-621.
33. Aggarwal S, He T, Fitzhugh W, et al. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. Gynecol Oncol. 2009;115:430-437.
34. Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet. 2014;124:1-5.
35. Matsuo K, Serada S, Hiramatsu K, et al. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int J Cancer. 2018;142:1056-1066.
36. Yokoyama T, Enomoto T, Serada S, et al. Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer. Int J Cancer. 2013;132:472-484.
37. Hiramatsu K, Serada S, Enomoto T, et al. LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake. Cancer Res. 2018;78:516-527.
38. Jilaveanu LB, Szoln J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Hum Pathol. 2012;43:1394-1399.
39. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.
40. Matsuzaki S, Enomoto T, Serada S, et al. Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A. Int J Cancer. 2014;134:1796-1809.
41. Koh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer. 1992;66:1109-1115.
42. Creative Biolabs. CD70 Therapeutic Antibody (Vorsetuzumab) https://www.creativebiolabs.net/Anti-Human-CD70-Therapeutic Antibody-vorsezumab-13746.htm (accessed on 05/29/2021).
43. Nishigaki T, Takahashi T, Serada S, et al. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020;122:1333-1341.
44. Matsuo K, Matsuzaki S, Nusbaum DJ, et al. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2021;160:32-39.
45. Meyer LA, He W, Sun CC, et al. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018;150:451-459.
46. Meyer LA, Cronin AM, Sun CC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2016;34:3854-3863.
47. Rauh-Hain JA, Melamed A, Wright A, et al. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer: analysis of the National Cancer Database. JAMA Oncol. 2017;3:76-82.
48. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
49. Keohne S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249-257.
50. Matsuo K, Eno ML, Im DD, Rosenshein NB. Chemotherapy time resistance after neoadjuvant chemotherapy compared to primary
surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;129:63-68.
50. Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31:18-23.
51. Gemtuzumab Ozogamicin Makes a Comeback. Cancer Discov. 2017;7:1208.
52. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619-626.
53. Moore KN, Martin LP, O'Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35:1112-1118.
54. Owonikoko TK, Hussain A, Stadler WM, et al. First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol. 2016;77:155-162.
55. Pal SK, Forero-Torres A, Thompson JA, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. Cancer. 2019;125:1124-1132.
56. Sonego M, Pellizzari I, Dall'Acqua A, et al. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci Rep. 2017;7:7104.
57. Busschots S, O'Toole S, O'Leary JJ, Stordal B. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. Exp Cell Res. 2015;336:1-14.
58. Ofzagolglu E, Stone UJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008;14:6171-6180.
59. Sanchez-Perez I, Benitah SA, Martinez-Gomariz M, Lacal JC, Perona R. Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol Biol Cell. 2002;13:2933-2945.
60. Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res. 2012;72:3664-3676.
61. Hara H, Takahashi T, Serada S, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br J Cancer. 2016;115:66-75.
62. Hiramatsu K, Yoshino K, Serada S, et al. Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas. Br J Cancer. 2016;114:554-561.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Shiomi M, Matsuzaki S, Serada S, et al. CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Sci. 2021;112:3655-3668. https://doi.org/10.1111/cas.15027